FDA approves Lundbeck's schizophrenia treatment for teenagers
Following the green light from US health authorities, schizophrenia treatment Rexulti may now be used in patients as young as 13 years in the US.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
On Thursday, Lundbeck and partner Otsuk received the green light from the US Food and Drug Administration (FDA) to expand the use of the schizophrenia treatment to include patients aged 13 to 17 years, reports a shared press release.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.